Clinical trials: Diabete Type 2
Diabetes Mellitus, Diabetes Mellitus, Type 2
A Virtual Cardiometabolic Health Program for African Immigrants: The Afro-DPP Program
A pilot study titled "A Virtual Cardiometabolic Health Program for African Immigrants (The Afro-DPP Program) will be conducted to address the cardiometabolic of community-dwelling African immigrants who have multiple…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, PreDiabetes, Hypertension
- Trial name
- NCT05144737
- Testing
- The Diabetes Prevention Program
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Johns Hopkins University
Diabetes Mellitus, Type 2
A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes
The main purpose of this study is to compare the safety and effectiveness of the study drug known as LY2944876 to exenatide extended-release and placebo in participants with type 2 diabetes mellitus.
- Trial name
- NCT02119819
- Testing
- LY2944876, Exenatide extended-release, Metformin
- Where
- 51 sites in United States, Greece and 4 more
- Volunteers
- 420 people
- Sponsor
- OPKO Health, Inc.
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate the Safety of Levemir® in Diabetes
This study is conducted in Africa, Asia, Europe, Japan and South America. The aim of this observational study is to evaluate the incidence of serious adverse reactions (SARs) while using Levemir® (insulin detemir) under normal…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PREDICTIVE™ (NCT00659295)
- Testing
- insulin detemir
- Where
- 13 sites in Belgium, Czechia and 11 more
- Volunteers
- 51,170 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of PF-06291874 in Type 2 Diabetes patients.
- Trial name
- NCT01856595
- Testing
- PF-06291874
- Where
- 3 sites in United States
- Volunteers
- 117 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.
The study compares 2 medicines for people with type 2 diabetes: insulin 287 (a new medicine) and insulin glargine (a medicine doctors can already prescribe).
- Trial name
- NCT03751657
- Testing
- Insulin icodec, Metformin, Dipeptidyl peptidase-4 inhibitors
- Where
- 49 sites in United States, Canada and 5 more
- Volunteers
- 247 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Obesity
Vagal Nerve Stimulation and Glucose Metabolism
The overall aim of this application is to determine the mechanism(s) by which common bariatric surgical procedures alter carbohydrate metabolism.
- Conditions
- Type 2 Diabetes, Obesity, Gastric Emptying
- Trial name
- NCT01117311
- Testing
- VNB on, VNB off
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Type 2 Diabetes Mellitus
Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus
This study is designed as a prospective, multi-centre, parallel group, double-blind randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of MP-513 (Teneligliptin) in combination with…
- Trial name
- NCT02924064
- Testing
- Teneligliptin 20mg, Metformin ≥ 1000 mg
- Where
- China
- Volunteers
- 247 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus
Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.
The purpose of this study is to determine the efficacy and safety of alogliptin, once daily (QD), taken in combination with insulin for the treatment of Type 2 Diabetes.
- Trial name
- NCT00286429
- Testing
- Alogliptin and insulin, Insulin
- Where
- 60 sites in United States, Argentina and 14 more
- Volunteers
- 390 people
- Sponsor
- Takeda
Diabetes
Dexcom G6 Observational Study
This is an exploratory prospective study primary aiming to evaluate differences between Point-of-care (POC) testing (standard of care) and Dexcom G6 CGM (Continues Glucose Monitoring sensor system) in 1) glycemic control measured…
- Trial name
- NCT03832907
- Testing
- Dexcom G6 CGM - Continues Glucose Monitoring sensor system, POC BG - Point-of-Care Blood Glucose monitoring
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Emory University
Type 1 Diabetes, Type 2 Diabetes
Autologous Adult Stem Cells to Patients With Type 1 Diabetes and a Successful Renal Transplant
This is a phase I study to assess the safety and tolerability of infusing expanded stem cells into the pancreas of patients with type I diabetes and a successful renal transplant.
- Trial name
- NCT00788827
- Testing
- Autologous CD34+ stem cells
- Where
- United Kingdom
- Volunteers
- 7 people
- Sponsor
- Imperial College London
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus
The Investigator hypothesize that Dapagliflozin will improve EPC number and function AND Saxagliptin in addition to Dapagliflozin (additive effect) may improve EPC number and function even more than Dapa alone, compared to…
- Trial name
- NCT03660683
- Testing
- Dapagliflozin 10mg, Saxagliptin 5mg
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sabyasachi Sen
Type 2 Diabetes Mellitus
Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes
Sitagliptin is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-IV), and has been shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes mainly through incretin hormone-mediated…
- Trial name
- JANUB48 (NCT01334229)
- Testing
- Sitagliptin
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Laval University
Diabetes Mellitus, Type 2
An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions
The aim of this study is to demonstrate bioequivalence of fixed dose combination Dapagliflozin + Metformin modified -release, film-coated tablets, 10 mg + 1000 mg, (AstraZeneca AB, Sweden) versus Forxiga™ (Dapagliflozin)…
- Trial name
- NCT02722239
- Testing
- Xigduo XR, Metformin ER (Glucophage® long), Dapagliflozin (Forxiga)
- Where
- Russia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes
Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes
The purpose of this study is to evaluate the use of SMBG and CGM for clinical decisions related to the management of type 2 diabetes.
- Trial name
- REACT3 (NCT01237301)
- Testing
- CGM Group, SMBG Group
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- HealthPartners Institute
Diabetes Mellitus, Type 2
OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck.
This is an open-label, single-center, randomized, 2-way crossover study to evaluate the bioequivalence of OXEMET™ 1000 mg coated tablets, relative to 1000 mg of the reference product administered as two 500 mg tablets, under…
- Trial name
- NCT01842620
- Testing
- Metformin
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
The Effectiveness of Intervention on Insulin Injection
The aim of the study is to assess the effectiveness of an intervention for insulin injection initiation based on the Transtheoretical Model (TTM) for insulin-naïve patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03324451
- Testing
- TTM Intervention for Insulin Initiation, Usual care
- Where
- Taiwan
- Volunteers
- 151 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Diabetes Mellitus, Type 2
Effect of Inpatient Diabetes Management on Outpatient Glycemic Control
The hypothesis of this study is that using hospital admission to identify patients with poorly controlled diabetes (hemoglobin A1c levels >8%), and intervening during the hospitalization with targeted inpatient diabetes…
- Trial name
- NCT00869362
- Testing
- Diabetes management team
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Type 2
Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)
The general aim of the present study is to investigate the impact of 4 weeks treatment with linagliptin (5 mg) on endothelial function in patients with type 2 diabetes mellitus.
- Trial name
- NCT01703286
- Testing
- Linagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED)
A single dose, open label study to characterize the routes of elimination and determine the mass balance of MK-0941. A single 40 mg dose of MK-0941 will be given orally to male participants with type 2 diabetes.
- Trial name
- NCT00912002
- Testing
- MK-0941
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
Primary Objective: To demonstrate the noninferiority in the efficacy of Toujeo® to Tresiba® in glycated hemoglobin (HbA1c) change from Baseline to Week 24.
- Trial name
- BRIGHT (NCT02738151)
- Testing
- Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment
- Where
- 158 sites in United States, Bulgaria and 14 more
- Volunteers
- 929 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.